In a 2007 New England Journal of Medicine Phase III trial of about 412 patients, 2 mg of tesamorelin a day cut visceral fat by roughly 15% over 26 weeks, while the placebo group gained a little
If you are struggling with weight loss and are considering medication assisted treatment, contact Vive Ageless Weight Loss to schedule a consultation
While not statistically significant, the 3.0 and 4.5 g/d groups displayed greater mean increases in thigh girth with sprinting compared with baseline while the 1.5 g/d group exhibited the same relative leg pump
Subsequently, other drugs such as Novos Victoza (liraglutide, approved in 2010), AstraZenecas Bydureon (exenatide, 2012), GSKs Tanzeum (albiglutide, 2014), Lillys Trulicity (dulaglutide, 2014) and Novos Ozempic (semaglutide, 2017) and Rybelsus (oral semaglutide, 2019) were approved